Losmapimod: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -18% 1 48 Improvement, Studies, Patients Relative Risk RCTs -18% 1 48 Late -18% 1 48 Losmapimod for COVID-19 c19early.org December 2025 Favorslosmapimod Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ LOSVID Ziegler (DB RCT) -18% 1.18 [0.79-1.76] progression 16/22 16/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Late treatment -18% 1.18 [0.79-1.76] 16/22 16/26 18% higher risk All studies -18% 1.18 [0.79-1.76] 16/22 16/26 18% higher risk 1 losmapimod COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Effect extraction pre-specified(most serious outcome) Favors losmapimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ LOSVID Ziegler (DB RCT) -14% 1.14 [0.67-1.95] no recov. 18 (n) 24 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -14% 1.14 [0.67-1.95] 18 (n) 24 (n) 14% higher risk All studies -14% 1.14 [0.67-1.95] 18 (n) 24 (n) 14% higher risk 1 losmapimod COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Favors losmapimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ LOSVID Ziegler (DB RCT) -18% 1.18 [0.79-1.76] progression 16/22 16/26 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Late treatment -18% 1.18 [0.79-1.76] 16/22 16/26 18% higher risk All studies -18% 1.18 [0.79-1.76] 16/22 16/26 18% higher risk 1 losmapimod COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Effect extraction pre-specified(most serious outcome) Favors losmapimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ LOSVID Ziegler (DB RCT) -18% 1.18 [0.79-1.76] progression 16/22 16/26 Improvement, RR [CI] Treatment Control LOSVID Ziegler (DB RCT) -14% 1.14 [0.67-1.95] no recov. 18 (n) 24 (n) LOSVID Ziegler (DB RCT) -10% 1.10 [0.82-1.47] no recov. 22 (n) 25 (n) Losmapimod COVID-19 outcomes c19early.org December 2025 Favors losmapimod Favors control